| Income statement (USD) | Q4 2026 ended May 31, 2026 | Q3 2026 ended Feb 28, 2026 | Q2 2026 ended Nov 30, 2025 | Q1 2026 ended Aug 31, 2025 | Q4 2025 ended May 31, 2025 | Q3 2025 ended Feb 28, 2025 | Q2 2025 ended Nov 30, 2024 | Q1 2025 ended Aug 31, 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 875.0K | 987.0K | 1.21M | 1.38M | 749.0K | 1.12M | 1.64M | 1.81M |
| Cost of revenue | 946.0K | 1.03M | 1.16M | 956.0K | 993.0K | 1.10M | 1.20M | 1.52M |
| Gross profit | -71.0K | -44.0K | 51.0K | 424.0K | -244.0K | 19.0K | 437.0K | 289.0K |
| Research and development | 205.0K | 178.0K | 193.0K | 212.0K | 252.0K | 217.0K | 257.0K | 297.0K |
| Selling, general and admin | 1.26M | 1.08M | 1.23M | 1.33M | 1.07M | 1.01M | 1.17M | 1.36M |
| Operating expenses | 1.46M | 1.25M | 1.42M | 1.54M | 1.32M | 1.23M | 1.43M | 1.66M |
| Operating income | -1.53M | -1.30M | -1.37M | -1.12M | -1.56M | -1.21M | -993.0K | -1.37M |
| EBITDA | -1.52M | -1.28M | -1.35M | -1.10M | -1.54M | -1.19M | -971.0K | -1.35M |
| Income before tax | -1.14M | -1.30M | -1.31M | 5.0K | -1.54M | -1.17M | -953.0K | -1.31M |
| Income tax | 6.0K | 8.0K | 5.0K | 3.0K | 5.0K | -4.0K | -3.0K | 4.0K |
| Net income | -1.15M | -1.31M | -1.32M | 2.0K | -1.54M | -1.16M | -950.0K | -1.32M |
| EPS | -0.38 | -0.44 | -0.45 | 0.00 | -0.69 | -0.48 | -0.06 | -0.63 |
| EPS (diluted) | -0.38 | -0.44 | -0.45 | 0.00 | -0.69 | -0.48 | -0.06 | -0.63 |
| Diluted shares | 62.9K | 3.01M | 2.91M | 2.64M | -30.1K | 2.40M | 2.14M | 2.10M |
From Biomerica Inc.'s 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.